DBpedia – Linked Data Fragments

Matches in DBpedia 2015-10 for { ?s ?p "Cobicistat, with trade name Tybost (formerly GS-9350) is a licensed drug for use in the treatment of infection with the human immunodeficiency virus (HIV).Like ritonavir (Norvir), cobicistat is of interest for its ability to inhibit liver enzymes that metabolize other medications used to treat HIV, notably elvitegravir, an HIV integrase inhibitor. By combining cobicistat with elvitegravir, higher concentrations of the latter are achieved in the body with lower dosing, theoretically enhancing elvitegravir's viral suppression while diminishing its adverse side-effects. In contrast with ritonavir, the only other booster approved for use as a part of HAART, cobicistat has no anti-HIV activity of its own.Cobicistat is a component of the four-drug, fixed-dose combination HIV treatment elvitegravir/cobicistat/emtricitabine/tenofovir (marketed as Stribild, and also known as the "Quad Pill"). Stribild was approved by the FDA in August 2012 for use in the United States and is owned by Gilead Sciences. Additionally, in existence are a fixed-dose combination of Cobicistat and protease inhibitor Darunavir (darunavir/cobicistat; marketed as Prezcobix, by Janssen Therapeutics), and a fixed-dose combination of Cobicistat and protease inhibitor Atazanavir (atazanavir/cobicistat; marketed as Evotaz, by Bristol-Myers Squibb). Both Prezcobix and Evotaz were approved by the FDA in January 2015.Cobicistat is a potent inhibitor of cytochrome P450 3A enzymes, including the important CYP3A4 subtype. It also inhibits intestinal transport proteins, increasing the overall absorption of several HIV medications, including atazanavir, darunavir and tenofovir alafenamide fumarate."@en }

• Cobicistat abstract "Cobicistat, with trade name Tybost (formerly GS-9350) is a licensed drug for use in the treatment of infection with the human immunodeficiency virus (HIV).Like ritonavir (Norvir), cobicistat is of interest for its ability to inhibit liver enzymes that metabolize other medications used to treat HIV, notably elvitegravir, an HIV integrase inhibitor. By combining cobicistat with elvitegravir, higher concentrations of the latter are achieved in the body with lower dosing, theoretically enhancing elvitegravir's viral suppression while diminishing its adverse side-effects. In contrast with ritonavir, the only other booster approved for use as a part of HAART, cobicistat has no anti-HIV activity of its own.Cobicistat is a component of the four-drug, fixed-dose combination HIV treatment elvitegravir/cobicistat/emtricitabine/tenofovir (marketed as Stribild, and also known as the "Quad Pill"). Stribild was approved by the FDA in August 2012 for use in the United States and is owned by Gilead Sciences. Additionally, in existence are a fixed-dose combination of Cobicistat and protease inhibitor Darunavir (darunavir/cobicistat; marketed as Prezcobix, by Janssen Therapeutics), and a fixed-dose combination of Cobicistat and protease inhibitor Atazanavir (atazanavir/cobicistat; marketed as Evotaz, by Bristol-Myers Squibb). Both Prezcobix and Evotaz were approved by the FDA in January 2015.Cobicistat is a potent inhibitor of cytochrome P450 3A enzymes, including the important CYP3A4 subtype. It also inhibits intestinal transport proteins, increasing the overall absorption of several HIV medications, including atazanavir, darunavir and tenofovir alafenamide fumarate.".